Please login to the form below

Not currently logged in
Email:
Password:

AVEO's financial head joins ImmunoGen

David Johnston appointed chief financial officer
David Johnston, Immunogen

David Johnston has left his role as chief financial officer of AVEO Pharmaceuticals to join ImmunoGen in the same role.

Johnston's switch comes after more than six years at AVEO having joined the company from his role as senior VP of finance corporate planning and analysis at Genzyme.

Other previous roles include VP finance and chief financial officer of Genzyme Biosurgery.

In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.

“I am delighted to have Dave join ImmunoGen,” commented ImmunoGen's CEO Daniel Junius.

“His depth of experience in both senior financial positions and in corporate planning makes Dave well-suited to help successfully advance the company to our next stages,” added Junius.

7th January 2014

From: Research, Sales

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics